Last reviewed · How we verify
NCT06605417: NevustoMel
Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
trial testing Methylomics in Congenital Melanocytic Nevi in 100 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Fundacion Clinic per a la Recerca Biomédica |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 January 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 2 locations across France, Spain |
Drugs / interventions tested
- Methylomics
- RNA sequencing
- Spatial transcriptomics
- Liquid biopsy — full drug profile →
Conditions studied
- Congenital Melanocytic Nevi — all drugs for Congenital Melanocytic Nevi →
- Melanoma, Skin — all drugs for Melanoma, Skin →
- Nevi and Melanomas — all drugs for Nevi and Melanomas →
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Who can join
Eligibility, any sex, with Congenital Melanocytic Nevi or Melanoma, Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are: * To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06605417
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fundacion Clinic per a la Recerca Biomédica trials
Trials by the same sponsor.
- NCT07454096 — Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study · Phase 4 · not yet recruiting
- NCT07412873 — Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer · Phase 4 · not yet recruiting
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT07105384 — Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear · Phase 2 · active not recruiting
- NCT06896617 — Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06605417 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinic per a la Recerca Biomédica
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06605417.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing